Following clinical trials also provided proof of concept of olaparib single-agent activity of PARP inhibition in patients with tumours that have genetic loss of function of BRCA1-associated or BRCA2-associated DNA repair [157,158]. This evidence concerns the gene BRCA1 and neoplasm.